Loading the company…
Loading the company…
In the last ten years FDA made 3 decisions for Alafair Biosciences (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2021 (2). The latest was on 2021-10-29.
| Family | Decisions on record |
|---|---|
| Hernia repair | 3 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2021-10-29 | 510(k) | K213163 | VersaWrap |
| 2021-03-09 | 510(k) | K203600 | VersaWrap |
| 2020-03-06 | 510(k) | K200311 | VersaWrap Tendon Protector |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Alafair Biosciences.
In 2025, Alafair Biosciences reported engagement with 442 surgeons and other clinicians in the states MedaRep covers, worth $315K in consulting, speaking, meals and travel for its device products, the most in Texas ($180K to 166). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Texas ($180K, 166 engaged), California ($61K, 51 engaged), North Carolina ($21K, 17 engaged), Indiana ($11K, 4 engaged), Pennsylvania ($9,541, 21 engaged).